Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00413777 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycystic Kidney, Autosomal Dominant

Interventions

DRUG: Tolvaptan

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

[object Object]